Literature DB >> 9613623

Limbic-cortical neuronal damage and the pathophysiology of schizophrenia.

J G Csernansky1, M E Bardgett.   

Abstract

Neurobiological studies of patients with schizophrenia suggest that abnormalities of both anatomy and function occur in limbic-cortical structures. An anatomical circuit links the functioning of the ventral striatum (i.e., nucleus accumbens) with the hippocampus and other limbic-cortical structures where neurobiological abnormalities have been found. In animals, lesions of limbic-cortical neurons cause decreases in glutamatergic input to the nucleus accumbens and are also associated with decreases in presynaptic dopamine release, increases in the density of D2-like dopamine receptors, and insensitivity to the actions of dopamine antagonists such as haloperidol. These experiments suggest a plausible pathophysiology of schizophrenia, in that schizophrenic symptoms may be caused by an abnormal dopaminergic state brought about by a primary limbic-cortical lesion and deficits in glutamatergic inputs to the ventral striatum.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9613623     DOI: 10.1093/oxfordjournals.schbul.a033323

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  16 in total

1.  Neural basis of novel and well-learned recognition memory in schizophrenia: a positron emission tomography study.

Authors:  B Crespo-Facorro; A K Wiser; N C Andreasen; D S O'Leary; G L Watkins; L L Boles Ponto; R D Hichwa
Journal:  Hum Brain Mapp       Date:  2001-04       Impact factor: 5.038

2.  Neonatal exposure to the glutamate receptor antagonist MK-801: effects on locomotor activity and pre-pulse inhibition before and after sexual maturity in rats.

Authors:  R. J. Beninger; A. Jhamandas; H. Aujla; L. Xue; R. V. Dagnone; R. J. Boegman; K. Jhamandas
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

3.  Segmenting magnetic resonance images via hierarchical mixture modelling.

Authors:  Carey E Priebe; Michael I Miller; J Tilak Ratnanather
Journal:  Comput Stat Data Anal       Date:  2006-01       Impact factor: 1.681

Review 4.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

5.  Northwestern University schizophrenia data sharing for SchizConnect: A longitudinal dataset for large-scale integration.

Authors:  Alex Kogan; Kathryn Alpert; Jose Luis Ambite; Daniel S Marcus; Lei Wang
Journal:  Neuroimage       Date:  2015-06-16       Impact factor: 6.556

6.  Pain sensitivity is altered in animals after subchronic ketamine treatment.

Authors:  Axel Becker; Gisela Grecksch; Helmut Schröder
Journal:  Psychopharmacology (Berl)       Date:  2006-10-03       Impact factor: 4.530

Review 7.  Some remarks on etiological aspects of early-onset schizophrenia.

Authors:  C Eggers
Journal:  Eur Child Adolesc Psychiatry       Date:  1999       Impact factor: 4.785

Review 8.  A neurobiological basis for substance abuse comorbidity in schizophrenia.

Authors:  R A Chambers; J H Krystal; D W Self
Journal:  Biol Psychiatry       Date:  2001-07-15       Impact factor: 13.382

9.  Clozapine functions through the prefrontal cortex serotonin 1A receptor to heighten neuronal activity via calmodulin kinase II-NMDA receptor interactions.

Authors:  Sudarshana Purkayastha; Jason Ford; Baishali Kanjilal; Souleymane Diallo; Joseph Del Rosario Inigo; Lorenz Neuwirth; Abdeslem El Idrissi; Zaghloul Ahmed; Andrzej Wieraszko; Efrain C Azmitia; Probal Banerjee
Journal:  J Neurochem       Date:  2011-12-15       Impact factor: 5.372

Review 10.  Timing as a window on cognition in schizophrenia.

Authors:  Ryan D Ward; Christoph Kellendonk; Eric R Kandel; Peter D Balsam
Journal:  Neuropharmacology       Date:  2011-04-21       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.